These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 37326075)
21. Free and total plasma malondialdehyde in chronic renal insufficiency and in dialysis patients. De Vecchi AF; Bamonti F; Novembrino C; Ippolito S; Guerra L; Lonati S; Salini S; Aman CS; Scurati-Manzoni E; Cighetti G Nephrol Dial Transplant; 2009 Aug; 24(8):2524-9. PubMed ID: 19264746 [TBL] [Abstract][Full Text] [Related]
22. Prophylactic hemodialysis following coronary angiography and one-year outcomes in non-dialysis patients with chronic kidney disease: A propensity-matched study. Chen HY; Ou SH; Chou KJ; Fang HC; Chen CL; Hsu CY; Huang CW; Chang C; Lee PT; Yang CH J Formos Med Assoc; 2021 Jan; 120(1 Pt 3):629-640. PubMed ID: 32709451 [TBL] [Abstract][Full Text] [Related]
23. Reduced hemodialysis-induced oxidative stress in end-stage renal disease patients by electrolyzed reduced water. Huang KC; Yang CC; Lee KT; Chien CT Kidney Int; 2003 Aug; 64(2):704-14. PubMed ID: 12846769 [TBL] [Abstract][Full Text] [Related]
24. Hemodialysis and effect of corrective measures to prevent hypoglycemia. Katla V; Khyalappa R J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443447 [TBL] [Abstract][Full Text] [Related]
25. Serum magnesium, mortality, and cardiovascular disease in chronic kidney disease and end-stage renal disease patients: a systematic review and meta-analysis. Xiong J; He T; Wang M; Nie L; Zhang Y; Wang Y; Huang Y; Feng B; Zhang J; Zhao J J Nephrol; 2019 Oct; 32(5):791-802. PubMed ID: 30888644 [TBL] [Abstract][Full Text] [Related]
26. Apolipoproteins A and B and PCSK9: Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease and in End-Stage Renal Disease. Vlad CE; Foia L; Popescu R; Ivanov I; Luca MC; Delianu C; Toma V; Statescu C; Rezus C; Florea L J Diabetes Res; 2019; 2019():6906278. PubMed ID: 31915710 [TBL] [Abstract][Full Text] [Related]
27. Nonalcoholic fatty liver disease (NAFLD)--is it a new marker of hyporesponsiveness to recombinant human erythropoietin in patients that are on chronic hemodialysis? Orlic L; Mikolasevic I; Lukenda V; Racki S; Stimac D; Milic S Med Hypotheses; 2014 Dec; 83(6):798-801. PubMed ID: 25456789 [TBL] [Abstract][Full Text] [Related]
28. Nationwide cohort study suggests that nucleos(t)ide analogue therapy decreases dialysis risk in Taiwanese chronic kidney disease patients acquiring hepatitis B virus infection. Chen YC; Li CY; Tsai SJ; Chen YC World J Gastroenterol; 2018 Feb; 24(8):917-928. PubMed ID: 29491685 [TBL] [Abstract][Full Text] [Related]
30. Neutrophil-to-lymphocyte ratio and incident end-stage renal disease in Chinese patients with chronic kidney disease: results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). Yuan Q; Wang J; Peng Z; Zhou Q; Xiao X; Xie Y; Wang W; Huang L; Tang W; Sun D; Zhang L; Wang F; Zhao MH; Tao L; He K; Xu H; J Transl Med; 2019 Mar; 17(1):86. PubMed ID: 30876475 [TBL] [Abstract][Full Text] [Related]
31. Zinc and Chronic Kidney Disease: A Review. Chen W; Lu H; Ying Y; Li H; Shen H; Cai J J Nutr Sci Vitaminol (Tokyo); 2024; 70(2):98-105. PubMed ID: 38684391 [TBL] [Abstract][Full Text] [Related]
34. Outcomes of stage 1-5 chronic kidney disease in Mainland China. Lai X; Zhang AH; Chen SY; He L; Su CY; Fan MH; Wang T Ren Fail; 2014 May; 36(4):520-5. PubMed ID: 24456114 [TBL] [Abstract][Full Text] [Related]
35. Outcomes in Patients With Chronic Kidney Disease and End-stage Renal Disease and Durable Left Ventricular Assist Device: Insights From the United States Renal Data System Database. Dalia T; Chan WC; Sauer AJ; Ranka S; Goyal A; Mastoris I; Pothuru S; Abicht T; Danter M; Vidic A; Gupta K; Tedford RJ; Cowger J; Fang JC; Shah Z J Card Fail; 2022 Nov; 28(11):1604-1614. PubMed ID: 35470059 [TBL] [Abstract][Full Text] [Related]
36. Impact of severity of renal dysfunction on determinants of in-hospital mortality among patients undergoing percutaneous coronary intervention. Parikh PB; Jeremias A; Naidu SS; Brener SJ; Lima F; Shlofmitz RA; Pappas T; Marzo KP; Gruberg L Catheter Cardiovasc Interv; 2012 Sep; 80(3):352-7. PubMed ID: 22566286 [TBL] [Abstract][Full Text] [Related]
38. Systematic review and meta-analysis of outcomes of lower extremity peripheral arterial interventions in patients with and without chronic kidney disease or end-stage renal disease. Anantha-Narayanan M; Sheikh AB; Nagpal S; Jelani QU; Smolderen KG; Regan C; Ionescu C; Ochoa Chaar CI; Schneider M; Llanos-Chea F; Mena-Hurtado C J Vasc Surg; 2021 Jan; 73(1):331-340.e4. PubMed ID: 32889074 [TBL] [Abstract][Full Text] [Related]
39. Frailty in end stage renal disease: Current perspectives. Nagaraju SP; Shenoy SV; Gupta A Nefrologia (Engl Ed); 2022; 42(5):531-539. PubMed ID: 36792307 [TBL] [Abstract][Full Text] [Related]
40. Coenzyme Q10 and its relation with oxidant and antioxidant system markers in patients with end-stage renal disease. Gokbel H; Atalay H; Okudan N; Solak Y; Belviranli M; Turk S Ren Fail; 2011; 33(7):677-81. PubMed ID: 21787158 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]